Neurology
Partner With Us
Advertisement

Rare Diseases

thumb description

November 20, 2024

CPPD Disease: More Common Than Previously Thought

In a paradigm shift for treating acute CPPD crystal arthritis, the 2023 COLCHICORT trial showed prednisone matched colchicine's efficacy with better tolerability in older patients, challenging long-held treatment assumptions.

Conexiant

thumb description

November 20, 2024

CPPD Disease: More Common Than Previously Thought

In a paradigm shift for treating acute CPPD crystal arthritis, the 2023 COLCHICORT trial showed prednisone matched colchicine's efficacy with better tolerability in older patients, challenging long-held treatment assumptions.

Conexiant

thumb description

November 19, 2024

Novel Stroke Drug Shows 12-Hour Window

Despite a median treatment time of 9.5 hours after stroke onset - more than twice the current therapeutic window - JX10 showed significantly better functional outcomes than placebo with no symptomatic intracranial hemorrhage events.

Conexiant

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

thumb description

November 12, 2024

Eight Off-Label Treatments Show Promise for ALS

While individual treatments targeting neuroinflammation, oxidative stress, or mitochondrial dysfunction have historically disappointed in ALS trials, eight alternative treatments showing multi-mechanism effects warrant further investigation, according to a comprehensive review of 15 years of clinical data.

Conexiant